THE USE OF ACUTE-PHASE PROTEINS APACHE II AND SOFA TO PREDICT THE MORTALITY OF COVID-19 PATIENTS

Basit Öğe Kaydı
dc.contributor.authorDeniz, Cigdem Damla
dc.contributor.authorVisneci, Emin Fatih
dc.contributor.authorEryilmaz, Mehmet Ali
dc.contributor.authorTutar, Mahmut Sami
dc.contributor.authorIyisoy, Mehmet Sinan
dc.contributor.authorUgur, Ayse Ruveyda
dc.contributor.authorKoc, Mehmet
dc.date.accessioned2024-02-23T14:49:35Z
dc.date.available2024-02-23T14:49:35Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractObjective: Acute-phase proteins are a family of proteins synthesized by the liver. With this study, we aimed to investigate the effects of COVID-19 infection on acute phase reactants (AFR) and determine the usability of AFRs as prognostic factors in COVID-19 disease.Material and Method: Serum samples taken for routine analysis of the patients admitted to the Emergency Department and diagnosed with COVID-19, were used. AFR levels of 30 patients who resulted in mortality and 30 recovered patients were evaluated. C-reactive protein (CRP), ferritin (FER), ceruloplasmin (Cp), albumin (Alb), prealbumin (Prealb), transferrin (Trf), lactate, Acute Physiology and Chronic Health Evaluation (APACHE), and Sequential Organ Failure Assessment (SOFA) assessment was performed.Results: The hazard ratio and 95% confidence interval for FER, CRP, lactate, Alb, Cp, Prealb, Trf, Age, SOFA, and APACHE were 1.001 (1.000-1.001), 1.005 (1.001- 1.008), 1.141 (1.016-1.243), 1.016 (0.740-1.399), 1.016 (0.740-1.399), 1.056 (1.017-1.100), 0.978 (0.917-1.035), 1.000 (0.995-1.006), 1.032 (1.004- 1.064), 1.104 (0.971-1.247), and 1.012 (0.974-1.051), respectively, in univariable model. Only CRP, lactate, and FER found significant in multivariable model. In addition, patients in the nonsurvivors group had significantly higher FER, CRP, lactate, APACHE, age, and SOFA. Nonsurvivors also had lower Alb, Prealb, and serum Trf level compared to survivors.Conclusion: CRP, lactate, and FER, which we have shown to be significantly higher in severe COVID-19 patients, will be valuable parameters that will contribute to clinical improvement if they are used in the follow-up of patients due to their easy measurement and predictive values.en_US
dc.identifier.endpage10en_US
dc.identifier.issn1305-2381
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage5en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/18255
dc.identifier.volume19en_US
dc.identifier.wosWOS:000986046000001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherNobel Ilacen_US
dc.relation.ispartofNobel Medicusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute-Phase Proteinsen_US
dc.subjectSurvivalen_US
dc.subjectCovid-19en_US
dc.subjectMortalityen_US
dc.subjectApacheen_US
dc.subjectSofaen_US
dc.titleTHE USE OF ACUTE-PHASE PROTEINS APACHE II AND SOFA TO PREDICT THE MORTALITY OF COVID-19 PATIENTSen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu